Change Healthcare (CHNG) Receives a Hold from Deutsche Bank

Deutsche Bank analyst George Hill maintained a Hold rating on Change Healthcare (CHNGResearch Report) on March 8 and set a price target of $25.75. The company’s shares closed last Tuesday at $22.06.

According to TipRanks.com, Hill is a 4-star analyst with an average return of 8.1% and a 56.6% success rate. Hill covers the Healthcare sector, focusing on stocks such as Molina Healthcare, 1Life Healthcare, and Cardinal Health.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Change Healthcare with a $25.75 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Change Healthcare’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $866 million and GAAP net loss of $24.47 million. In comparison, last year the company earned revenue of $785 million and had a net profit of $2.2 million.

Based on the recent corporate insider activity of 46 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CHNG in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Change Healthcare, Inc. operates as a healthcare technology company. It offers software, analytics, network solutions, and technology-enabled services. The firm’s products include ANSOS staff scheduling, HealthQx, hospital revenue cycle services, coding advisor, revenue performance advisor, and InterQual. The company was founded in 2007 and is headquartered in Alpharetta, GA.

Read More on CHNG:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed